



PAPAGAIO

OCTOBER NEWSLETTER

October 2025

WEBSITE: PAPAGAIO-I.ORG
EMAIL: PAPAGAIO@KCL.AC.UK

Welcome to the next edition of the
PAPAGAIO monthly newsletter!

Huge well done to **all** sites across
Zambia and **Brazil** who have maintained
a stellar rate of work throughout
September. **Ribeirão Preto** 🇧🇷 nearly
quadrupled their participant count!

Recruitment continued with a fantastic
rate in September, with **135** potential
🎉 participants screened!


We finished September with **104**
new participants randomised in the
PAPAGAIO trial, bringing our total to
318!

September stats:

Sites open: **6**

Participants randomised: **104**

September Participant Recruitment
Numbers




Site	Country	Date opened	Total screened	Total randomised	Screened (Sept)	Eligible (Sept)	Randomised (Sept)
Botucatu Medical School	BR	01/07/2025	96	94	32	32	32
Ribeirão Preto	BR	14/08/2024	18	18	13	13	13
Women's and Newborns University Teaching Hospital	ZM	15/07/2025	89	63	30	23	22
Ndola Teaching Hospital	ZM	17/07/2025	75	59	22	17	15
Kitwe Teaching Hospital	ZM	17/07/2025	54	42	20	12	11
Kabwe General Hospital	ZM	16/07/2025	62	42	18	11	11
GRAND TOTAL			394	318	135		104

PARTICIPANT TRACKER

GOAL: 1310

Current: 318





PAPAGAIO In Practice

We are seeing cases come through where the use of PIGF testing appears to have positively influenced clinical outcomes!

A woman presented with **mild proteinuria** and **new hypertension** at around **33 weeks'** gestation. She was randomised to the test arm, and found to have a **normal PIGF**.

This woman was able to be safely **managed as an outpatient** with careful monitoring, and her pregnancy continued till she went into **spontaneous labour** at **term**. She and baby were discharged home safely!

A woman presented with **mild hypertension** and **severe proteinuria** at **34 weeks'** gestation. She was randomised to the test arm, and found to have a **normal PIGF**.

This led to a diagnosis of **Glomerulopathy** rather than pre-eclampsia, and was able to be safely observed until she reached **term gestation**. She and baby were discharged home safely!

These cases are a testament to what PAPAGAIO-Diagnosis is all about! Keep up the good work everyone 🙌



PAPAGAIO at FIGO!

Many PAPAGAIO Teams were in Cape Town, South Africa at the start of October for the FIGO Conference!





NOTICES

Data entry clarification

The Signs and Symptoms at Enrolment page applies to what a participant has experienced in the past **48 hours**, not just at the point of enrolment.

For example, if they presented with a headache the day before that has since resolved, this should be entered on the page.

We are keen to include interesting case stories in future newsletters. If you have any good examples of where the PIGF result was able to positively influence the care of a patient, please share them with the team at PAPAGAIO@kcl.ac.uk

Thank you to all sites who have sent their site files through so far!

DOCUMENTATION

Please endeavour to send your master consent forms and patient information leaflets (if translated from English) to the PAPAGAIO email address this month. We also require completed delegation of duties logs, and equipment agreement forms from each site that is open!

Please send all paperwork to papagaio@kcl.ac.uk

THANK YOU!

Please circulate this newsletter with anyone involved in PAPAGAIO who might find it helpful. If a colleague would like to be added to the mailing list, please send an email to PAPAGAIO@kcl.ac.uk

THANK YOU ALL FOR YOUR HARD WORK